IMP: BOD resolution dated Oct 28, 2022
The Board resolution dated October 28, 2022, the Board of Directors of Imexpharm Corporation approved the following contents:
- Revenue: 347.9 billion dongs
- Profit: 77.5 billion dongs.
HOSE
> PHR: BOD resolution dated Oct 31, 2022 (03/11/2022)
> CPNJ2203: Notice of adjustment of covered warrant (02/11/2022)
> TIX: Approved the Information disclosure Regulation (02/11/2022)
> SRC: Agreement with Hoanh Son Group (02/11/2022)
> BID: BOD resolution dated October 31, 2022 (02/11/2022)
> TIX: BOD resolution dated November 01, 2022 (02/11/2022)
> PHC: Receiving the transfer of shares (02/11/2022)
> HOSE: Proprietary Trading (02 Nov 2022) (02/11/2022)
> VSC: Cancellation of plan for share private placement in 2022 (02/11/2022)
> SBT: Board Resolution (02/11/2022)